Skip to content

US · LUCD · MEDICAL - DEVICES

Lucid Diagnostics Inc. (LUCD) intrinsic value and stock valuation

$0.37as of 2026-11-21 · Mkt cap 102.3M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lucid Diagnostics Inc. DCF and intrinsic value

InvestorsCraft values LUCD with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LUCD’s statements →

Lucid Diagnostics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices New York City, NY 10165 luciddx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$4.71M
20182025
Net income
-$-58.01M
20182025
Free cash flow
-$-46.48M
20182025
Total equity
$10.9M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$4.71M$4.35M$2.43M$380K$500K
Operating income-$-49.64M-$-46.05M-$-48.48M-$-56.17M-$-27.42M
Net income-$-58.01M-$-45.53M-$-52.67M-$-56.17M-$-28.08M
EPSd-$-569K-$-901.23K-$-1.26M-$-1.55M-$-778.7K
Operating cash flow-$-46.48M-$-44.14M-$-32.82M-$-29.68M-$-17.67M
Capital expenditure-$-200K-$-650K-$-220K-$-910K-$-860K
Free cash flow-$-46.48M-$-44.79M-$-33.04M-$-30.59M-$-18.53M
Total assets$40.5M$30.7M$27.3M$32.5M$59M
Total debt$25.8M$21.3M$15.3M$2M$0.00
Net debt-$-8.88M-$-1.1M-$-3.64M-$-20.48M-$-53.66M
Total equity$10.9M$5.39M-$-2.31M$23.1M$54.7M
Cash and short-term investments$34.7M$22.4M$18.9M$22.5M$53.7M
Income statement
20252024202320222021
Revenue$4.71M$4.35M$2.43M$380K$500K
Cost of revenue$7.54M$8.27M$8.48M$3.61M$580K
Gross profit-$-2.84M-$-3.92M-$-6.05M-$-3.24M-$-90K
Research and development expenses$5.68B$5.99M$7.25M$11.5M$9.3M
Selling, general and administrative expenses$41.6B$36.6B$35.7M$39.8M$18M
Other expenses-$-47.21B-$-36.58B-$-480K$1.65M$0.00
Operating expenses$46.8M$42.1M$42.4M$52.9M$27.3M
Cost and expenses$54.4M$50.4M$50.9M$56.6M$27.9M
Interest income$390K$320K$420K$90K$0.00
Interest expense$20K$30K$420K$10K$660K
Depreciation and amortization$870K$1.17M$2.5M$1.94M$0.00
Ebitda-$-57.12M-$-44.34M-$-49.75M-$-54.23M-$-27.41M
Operating income-$-49.64M-$-46.05M-$-48.48M-$-56.17M-$-27.42M
Total other income/expenses, net-$-8.37M$520K-$-4.18M$0.00-$-660K
Income before tax-$-58.01M-$-45.53M-$-52.67M-$-56.17M-$-28.08M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-58.01M-$-45.53M-$-52.67M-$-56.17M-$-28.08M
Weighted average shares outstanding$102M$50.5M$41.8M$36.2M$36.1M
Weighted average diluted shares outstanding$102M$50.5M$41.8M$36.2M$36.1M
Balance sheet
20252024202320222021
Cash and short-term investments$34.7M$22.4M$18.9M$22.5M$53.7M
Net receivables$640K$410K$40K$20K$200K
Inventory$350K$340K$280K$110K$490K
Total current assets$37.5M$25.2M$22.1M$24.4M$57.3M
Property, plant and equipment, net$2.62M$3.7M$2.64M$3.6M$970K
Goodwill and intangible assets$320K$740K$1.42M$3.44M$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.98M$5.57M$5.2M$8.15M$1.7M
Total assets$40.5M$30.7M$27.3M$32.5M$59M
Accounts payable$970K$1.24M$1.15M$1.06M$1.49M
Short-term debt$24.9M$19.5M$15.1M$960K$0.00
Deferred revenue$0.00$0.00$940K$0.00$0.00
Total current liabilities$28.6M$23.5M$29.4M$8.43M$4.26M
Long-term debt$930K$1.8M$200K$1.04M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$930K$1.8M$200K$1.04M$0.00
Capital lease obligations$1.82M$2.65M$1.3M$2M$0.00
Total liabilities$29.5M$25.3M$29.6M$9.46M$4.26M
Common stock$130K$60K$40K$40K$40K
Retained earnings-$-274.33M-$-203.77M-$-150.74M-$-98.08M-$-41.9M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$10.9M$5.39M-$-2.31M$23.1M$54.7M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$25.8M$21.3M$15.3M$2M$0.00
Net debt-$-8.88M-$-1.1M-$-3.64M-$-20.48M-$-53.66M
Cash flow statement
20252024202320222021
Net income-$-58.01M-$-45.53M-$-52.67M-$-56.17M-$-28.08M
Depreciation and amortization$870K$1.17M$2.5M$1.94M$0.00
Stock-based compensation$4.49M$4.53M$6.82M$15M$9.6M
Change in working capital-$-2.81M-$-4.43M$5.67M$8.91M$810K
Accounts receivable-$-600K$0.00-$-30K$180K-$-200K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-270K$100K$90K-$-450K-$-670K
Net cash provided by operating activities-$-46.48M-$-44.14M-$-32.82M-$-29.68M-$-17.67M
Investments in property, plant and equipment-$-200K-$-300K-$-220K-$-910K-$-860K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-200K-$-650K-$-220K-$-4.11M-$-860K
Common stock issued$58.7M$450K$280K$1.81M$77.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$59M$48.3M$29.5M$2.61M$72.1M
Net change in cash$12.4M$3.46M-$-3.58M-$-31.18M$53.5M
Cash at end of period$34.7M$22.4M$18.9M$22.5M$53.7M
Operating cash flow-$-46.48M-$-44.14M-$-32.82M-$-29.68M-$-17.67M
Capital expenditure-$-200K-$-650K-$-220K-$-910K-$-860K
Free cash flow-$-46.48M-$-44.79M-$-33.04M-$-30.59M-$-18.53M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lucid Diagnostics Inc.

        Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.

        CEO
        Lishan Aklog
        Employees
        82
        Beta
        1.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Lucid Diagnostics Inc. (LUCD)?

        InvestorsCraft does not currently publish an intrinsic value for LUCD. How the IC value is calculated.

        Is LUCD undervalued?

        InvestorsCraft does not publish an undervaluation signal for LUCD at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.